|Day Low/High||42.50 / 42.74|
|52 Wk Low/High||32.69 / 42.58|
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a label update for FARXIGA ® (dapagliflozin) and XIGDUO ® XR (dapagliflozin and metformin HCl extended-release) expanding use in patients with type 2 diabetes (T2D)...
The Phase III THEMIS trial met its primary endpoint which demonstrated that BRILINTA ® (ticagrelor) tablets, taken in conjunction with aspirin, showed a statistically-significant reduction in major adverse cardiovascular events (MACE, a composite of...
Guardant's liquid biopsy lets oncologists see all of the genomic information of a patient's tumor with a simple blood test. The alternative is a tissue biopsy which can be expensive and risky.
U.S. equity futures turned sharply red Thursday after data showed the weakest reading for December retail sales in nine years, erasing earlier gains linked to progress in trade talks between Washington and Beijing and data showing a surprise jump in January China export activity.
SAN DIEGO, Feb. 14, 2019 /PRNewswire/ -- Tanabe Research Laboratories U.
What trader has never both fallen in love with Nvidia, only to eventually feel the scorn of an angry lover's tortured vengeance?
Wall Street futures extended gains Thursday with investors using signals of moderate progress in trade talks between Washington and Beijing and data showing a surprise jump in January China export activity to boost the broadest measure of U.S. stocks to a 10% gain for the year.
AstraZeneca shares traded sharply higher Thursday after the U.K.-based drugmaker posted stronger-than-forecast fourth quarter earnings, and said 2019 revenues would continue to rise, thanks to increasing demand for its key cancer treatments.
These companies are working to plant their flag in a new landscape.
One of pharma's biggest CEO's talks M&A action on the exchange.
TOKYO and LONDON, January 7, 2019 /PRNewswire/ -- Milestone achieved with next generation immuno-oncology candidate AZD4635, a novel adenosine 2A receptor antagonist Sosei Group Corporation ("the Company"; TSE: 4565), announces it has been notified today...
AstraZeneca today announced that the Phase III OLYMPUS and ROCKIES trials for roxadustat each met their primary efficacy endpoint for the treatment of patients with anemia in chronic kidney disease (CKD) that are either non-dialysis-dependent (NDD) or...
AstraZeneca and Merck & Co., Inc.
- Pyramid Biosciences to exclusively develop AstraZeneca's novel cell surface receptor (TRK) program
AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, have presented new, long-term follow-up results for CALQUENCE ® (acalabrutinib) in patients with relapsed or refractory mantle cell lymphoma (MCL) and updated...
AstraZeneca, together with Acerta Pharma, its hematology research and development center of excellence, and MedImmune, its global biologics research and development arm, will present 27 abstracts, including six oral presentations, at the 2018 American...
AstraZeneca today announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA (dapagliflozin).
AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular (CV) outcomes trial (CVOT) DECLARE (Dapagliflozin Effect on Cardiovascular Events)-TIMI 58, the broadest SGLT2...
AstraZeneca will present new research spanning the Company's Cardiovascular, Renal and Metabolism (CVRM) therapy area at the American Society of Nephrology (ASN) Kidney Week Annual Meeting in San Diego, US, October 23-28, 2018.
AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of IMFINZI ® (durvalumab) during the Presidential Symposium of the IASLC 19th World Conference on...
AstraZeneca today announced the first shipment of FLUMIST ® QUADRIVALENT (Influenza Vaccine Live, Intranasal) doses in the US for the 2018-2019 influenza season.
AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA ® (dapagliflozin), the broadest SGLT-2 inhibitor CVOT conducted to date.
AstraZeneca today announced results from the Phase III extension BORA trial evaluating the long-term safety and efficacy of FASENRA™ (benralizumab) as an add-on maintenance treatment in patients with severe eosinophilic asthma who had previously completed...
Both biotech stocks are at or near 52-week lows, but don't deserve to be.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.